Brief: Kura Oncology And Kyowa Kirin Announce First Patient Dosed In Pivotal Phase 3 Komet-017 Trial
29/09/2025 23:19
Sept 29 (Reuters) - Kyowa Kirin Co Ltd 4151.T: KURA ONCOLOGY AND KYOWA KIRIN ANNOUNCE FIRST PATIENT DOSED IN PIVOTAL PHASE 3 KOMET-017 TRIAL OF ZIFTOMENIB FOR FRONTLINE ACUTE MYELOID LEUKEMIA (AML) Source text: ID:nGNX8r8hcJ Further company coverage: 4151.T (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia